Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States

被引:25
作者
Armstrong, April W. [1 ,4 ]
Patel, Manish [2 ]
Li, Chao [2 ]
Garg, Vishvas [2 ]
Mandava, Monika Rao [2 ]
Wu, Jashin J. [3 ]
机构
[1] Univ Southern Calif, Los Angeles, CA USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Miami, Dept Dermatol, Miller Sch Med, Miami, FL USA
[4] Dermatol, Hc4 2000 1450 San Pablo, Hlth Sci Campus, Los Angeles, CA 90033 USA
关键词
Biologics; psoriasis; real-world evidence; treatment patterns; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; NATIONAL PSORIASIS; PLAQUE PSORIASIS; PHASE-III; MODERATE; EFFICACY; THERAPY; SAFETY; MONOTHERAPY;
D O I
10.1080/09546634.2023.2200870
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Switching therapies is common for patients with psoriasis. Objective To quantify real-world switching rates and characteristics among patients initiating biologics over 24 months. Methods Patients aged >= 18 years with >= 2 confirmed psoriasis diagnoses who initiated a new biologic were identified from a US-payer claims database (Merative (R) MarketScan (R)) Switching rates were reported over 24 months using Kaplan-Meier survival analysis, and multivariable Cox regression analyses were performed to identify associated patient characteristics. Results A total of 7997 patients were included, with overall treatment switch rates at 14.4% at 12 months and 26.0% at 24 months. IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months (p < 0.0001). Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months. Prior targeted immune modulator use, age, and female gender were predictors of switching (adjusted hazard ratio; 1.23, 1.31, and 1.40, respectively; p <= 0.0005). Limitations Claims data may be subject to data errors and reasons for switching cannot be determined. Conclusion Switching was common in psoriasis patients using biologics over 24 months, with the lowest risk of switching observed with IL-23 inhibitors.
引用
收藏
页数:8
相关论文
共 29 条
[1]   Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review [J].
Armstrong, April W. ;
Read, Charlotte .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19) :1945-1960
[2]   From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis [J].
Armstrong, April W. ;
Siegel, Michael P. ;
Bagel, Jerry ;
Boh, Erin E. ;
Buell, Megan ;
Cooper, Kevin D. ;
Duffin, Kristina Callis ;
Eichenfield, Lawrence F. ;
Garg, Amit ;
Gelfand, Joel M. ;
Gottlieb, Alice B. ;
Koo, John Y. M. ;
Korman, Neil J. ;
Krueger, Gerald G. ;
Lebwohl, Mark G. ;
Leonardi, Craig L. ;
Mandelin, Arthur M. ;
Menter, M. Alan ;
Merola, Joseph F. ;
Pariser, David M. ;
Prussick, Ronald B. ;
Ryan, Caitriona ;
Shah, Kara N. ;
Weinberg, Jeffrey M. ;
Williams, MaryJane O. U. ;
Wu, Jashin J. ;
Yamauchi, Paul S. ;
Van Voorhees, Abby S. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (02) :290-298
[3]  
Armstrong AW., 2021, JAMA DERMATOL, V157, P1
[4]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[5]   Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population [J].
Doshi, Jalpa A. ;
Takeshita, Junko ;
Pinto, Lionel ;
Li, Penxiang ;
Yu, Xinyan ;
Rao, Preethi ;
Viswanathan, Hema N. ;
Gelfand, Joel M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) :1057-U409
[6]  
Feldman SR, 2016, AM HEALTH DRUG BENEF, V9, P504
[7]   Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis [J].
Feldman, Steven R. ;
Zhao, Yang ;
Shi, Lizheng ;
Tran, Mary Helen .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (10) :874-888
[8]  
Foster Shonda A, 2016, J Manag Care Spec Pharm, V22, P396, DOI 10.18553/jmcp.2016.22.4.396
[9]   Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis [J].
Gooderham, M. ;
Pinter, A. ;
Ferris, L. K. ;
Warren, R. B. ;
Zhan, T. ;
Zeng, J. ;
Soliman, A. M. ;
Kaufmann, C. ;
Kaplan, B. ;
Photowala, H. ;
Strober, B. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (06) :855-865
[10]   Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis [J].
Gooderham, Melinda J. ;
Lynde, Charles ;
Turchin, Irina ;
Avadisian, Miriam ;
Labelle, Melanie ;
Papp, Kim A. .
JOURNAL OF DERMATOLOGY, 2022, 49 (01) :95-105